Paris, France and Camberley, UK – 8 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has expanded its assay development contract with Immunexpress, Inc. (Immunexpress), a U.S.-based molecular diagnostic company with the first FDA cleared host response test for
Visit PageCategory: Novacyt Group
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2019/04/NOVACYT_CP_Droits-de-vote_2019-Apr.pdf
Visit PageLiquidity Agreement Monthly Update and Total Voting Rights
Paris, France and Camberley, UK – 1 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised
Visit Page